Corton Capital’s BioCryst Pharmaceuticals BCRX Stock Holding History

Corton Capital’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-16,269	Closed	-$122K	–	343
2025 Q1	$122K	Sell	16,269 -16,068	-50%	-$130K	0.4%	113
2024 Q4	$243K	Sell	32,337 -7,154	-18%	-$54.3K	0.14%	191
2024 Q3	$300K	Buy	+39,491	New	+$300K	0.15%	189
2023 Q1	–	Sell	-11,520	Closed	-$132K	–	330
2022 Q4	$132K	Buy	+11,520	New	+$144K	0.11%	246

Other funds holding BCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Corton Capital's BCRX Position: Q2 2025 in Review

Corton Capital sold out of BioCryst Pharmaceuticals (BCRX) in Q2 2025, closing a stake of 16,269 shares — an estimated $122K sold.

Corton Capital first reported a position in BCRX in Q4 2022 and held it in 4 quarters. The position peaked at $300K in Q3 2024. 294 funds tracked by Wall St. Rank hold BCRX as of Q2 2025.

Corton Capital reported no remaining BioCryst Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
Corton Capital sold 16,269 BioCryst Pharmaceuticals shares in Q2 2025, an estimated $122K.
Corton Capital first reported a position in BioCryst Pharmaceuticals in Q4 2022 and held it in 4 quarters.
Corton Capital's BioCryst Pharmaceuticals position peaked at $300K in Q3 2024.
294 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2025.

Based on Corton Capital's 13F filing for Q2 2025, filed 5 Aug 2025.